Treatment with intravenous immunoglobulins in critical care of neuromuscular disorders

Infusionstherapie und Transfusionsmedizin

Volumn 24, Issue 3, 1997, Pages 171-177

  Stangel, M ^a   Gold, R ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunomodulation; lntravenous immunoglobulins; Neuromuscular disorders (acute therapy and intensive care with intravenous immunoglobulins)

Indexed keywords

IMMUNOGLOBULIN;

DATA ANALYSIS; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PURITY; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MEDICAL RECORD; MOTOR NEUROPATHY; MYASTHENIA GRAVIS; PLASMAPHERESIS; REVIEW; TREATMENT INDICATION;

HEPATITIS C VIRUS;

EID: 0030872844     PISSN: 10198466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Kaveri S-V, Dietrich G, Hurez V, Kazatchkine MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991;86:192-198.
2. Dwyer JM: Manipulating the immune system with immune globulins. N Engl J Med 1992;326:107-116.
3. Ronda N, Hurez V, Kazatchkine MD: Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993;64:65-72.
4. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, University consortium expert panel: Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-1870.
5. Otten A, Vermeulen M, Bossuyt PMM: Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 1995;9:359-361.
6. Thornton CA, Griggs PC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-268.
7. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD: Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104 (suppl 1):3-9.
8. Dietrich G, Kaveri S-V, Kazatchkine MD: Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 1992;62:S73-S81.
9. Hurez V, Kaveri SV, Kazatchkine MD: Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J Autoimmun 1993;6: 675-681.
10. Rosen FS: Putative mechanisms of the effect of intravenous gamma-globulin. Clin Immunol Immunopathol 1993;67:S41-S43.
11. van Schaik IN, Vermeulen M, Brand A: In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 1994;57 (suppl):15-17.
12. Rees J: Guillain-Barré syndrome. Clinical manifestations and directions for treatment. Drugs 1995;49: 912-920.
13. Hansen-Schmidt S, Silomon J, Keller F: Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996;28:451-453.
14. Imbach P, Barandum S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;i:1228-1231.
15. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Ja Chung K, Colan S, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
16. Strobel E, Wüllenweber J, Peters J: Nachweis und Nebenwirkungen von Isoantikörpern in intravenös applizierbaren Immunglobulinpräparaten. Infusionsther Transfusionsmed 1995;2:31-35.
17. Rütter GH: Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry 1994;57 (suppl):2-5.
18. Hénin Y, Maréchal V, Barré-Sinoussi F, Chermann J-C, Morgenthaler J-J: Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang 1988;54:78-83.
19. Kempf C, Jentsch P, Barré-Sinoussi F, Morgenthaler JJ, Morell A, Germann D: Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991;31:423-127.
20. Uemura Y, Uriyu K, Hirao Y, Takechi K, Ishikawa U, Nakajima T, Kagitani Y, Yokoyama K, Funakoshi S, Nishida M, Yabushita S, Furuta K, Hamamoto Y, Tochikura TS, Yamamoto N: Inactivation and elimination of viruses during the fractionation of an intravenous immunoglobulin preparation: Liquid heat treatment and polyethylene glycol fractionation. Vox Sang 1989;6:155-161.
21. Yap PL: The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104 (suppl 1):35-12.
22. Gutteridge CN, Veys P, Newland AC: Safety of intravenous immunoglobulin for treatment of autoimmune thrombocytopenia. Acta Haematol 1988; 79:88-90.
23. Imbach P, Perret BA, Babington R, Kaminski K, Morell A, Heiniger HJ: Safety of intravenous immunoglobulin preparations: A prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang 1991;61:240-243.
24. Lever AML, Webster ADB, Brown D, Thomas HC: Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984;ii:1062-1064.
25. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdon HS, Wedgwood RJ: Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1985;i:404-105.
26. Björklander J, Cunningham-Rundles C, Lundin P, Olsson R, Sönderström R, Hanson LA: Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-111.
27. Williams PE, Yap PL, Gillon J, Crawford RJ, Urbaniak SJ, Galea G: Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang 1989;57:15-18.
28. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
29. Flora K, Schiele M, Benner K, Montanaro A, Johnston W, Whitham R, Press R: An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. Ann Allergy Asthma Immunol 1996; 76:160-162.
30. Echevarriá JM, León P, Domingo CJ, López JA, Elola C, Madurga M, Salmerón F, Yap PL, Daub J, Simmonds P: Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion 1996;36:725-730.
31. Thornton CA, Ballow M: Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-136.
32. Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.
33. NIH consensus conference: Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264:3189-3193.
34. Duhem C, Dicato MA, Ries F: Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97 (suppl 1):79-83.
35. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47:647-677.
36. Oomes PG, van der Meche FGA, Kleyweg RP, Dutch Guillain-Barré Study Group: Liver function disturbances in Guillain-Barré syndrome: A prospective longitudinal study in 100 patients. Neurology 1996;46:96-100.
37. Ben-Chetrit E, Putterman C: Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992;326:270-271.
38. Casteels-van Daele M, Wijndaele L, Hunninck K: Intravenous immune globulin and acute aseptic meningitis. N Engl J Med 1990;323:614-615.
39. Constantinescu CS, Chang AP, McCluskey LF: Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584.
40. Dalakas MC: High-dose intravenous immunoglobulins and serum viscosity: Risk of precipitating thrombembolic events. Neurology 1994;44:223-226.
41. Silbert PL, Knezevic WV, Bridge DT: Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992; 42:257-258.
42. Steg RE, Lefkowitz DM: Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181.
43. Vera-Ramirez M, Charlet M, Parry GJ: Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1992;42:1636-1637.
44. Watson JDG, Gibson J, Joshua DE, Kronenberg H: Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1991;54:275-276.
45. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R: Reversible encephalopathy with vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46: 250-251.
46. Harkness K, Howell SJL, Davies-Jones GAB: Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996;60:586.
47. Koehler PJ, Koudstaal J: Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenytoin. J Neurol 1996;243: 366-367.
48. Lisak RP: Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88.
49. Brox AG, Cournoyer D, Sternbach M, Spurl G: Hemolytic anemia following intravenous gammaglobulin administration. Am J Med 1987;82: 633-635.
50. Ahsan N, Palmer BF, Wheeler D, Greenlee RG, Toto RD: Intravenous immunoglobulin-induced osmotic nephrosis. Arch Int Med 1994;154:1985-1987.
51. Rault R, Piraino B, Johnston JR, Oral A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.
52. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K: High-dose intravenous IgG treatment and renal function. Lancet 1991;337:457-458.
53. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50: 137-139.
54. Steward RRC, Winney RJ, Cash JD: Renal toxicity of intravenous immunoglobulin. Vox Sang 1993;65:244.
55. Woodruff RK, Gigg AP, Firkin FC, Smith IL: Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;ii:217-218.
56. Bertorini TE, Nance AM, Hörner LH, Greene W, Gelfand MS, Jaster JH: Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19:388-391.
57. Sekul EA, Culper EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.
58. Hartung H-P, Pollard JD, Harvey GK, Toyka KV: Immunopathogenesis and treatment of the Guillain-Barré syndrome - part II. Muscle Nerve 1995;18: 154-164.
59. Rostami AM: Guillain-Barré syndrome: Clinical and immunological aspects. Springer Semin Immunopathol 1995;17:29-42.
60. van der Meche FGA, van Doorn PA: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies. Ann Neurol 1995;37(S1):S14-S31.
61. Ropper AH: The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136.
62. Ng KKP, Howard RS, Fish DR, Hirsch NP, Wiles CM, Murray NMF, Miller DH: Management and outcome of severe Guillain-Barré syndrome. Q J Med 1995;88:243-250.
63. The Guillain-Barré syndrome study group: Plasma-pheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
64. French cooperative group on plasma exchange in Guillain-Barré syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987;22:753-761.
65. Kleyweg RP, van der Meche FGA, Meulstee J: Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988;38:1639-1641.
66. van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barré study group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
67. Bleck TP: IVIg for GBS: Potential problems in the alphabet soup. Neurology 1993;43:857-858.
68. Castro LHM, Ropper AH: Human immune globulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology 1993;43: 1034-1036.
69. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley. DF: Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.
70. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
71. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group: Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
72. Guillain-Barré syndrome steroid trial group: Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590.
73. The Dutch Guillain-Barré study group: Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neurol 1994;35:749-752.
74. Jacobs BC, Schmitz PIM, van der Meche FGA: Campylobacter jejuni infection and treatment for Guillain-Barré syndrome. N Engl J Med 1996;335: 208-209.
75. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G: Sequential treatment of Guillain-Barré syndrome with extracorporal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137: 145-149.
76. Haupt WF, Rosenow F, van der Ven C, Borberg H: Therapieassoziierte Fluktuationen beim Guillain-Barré-Syndrom und die Frage multipler Behandlungszyklen. Aktuel Neurol 1996;23:75-77.
77. Cornblath DR, Asbury AK, Albers JW, Feasby TE, Hahn AF, McLeod JG, Mendell JR, Parry GJ, Pollard JD, Thomas PK: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
78. Glass JD, Cornblath DR: Chronic inflammatory demyelinating polyneuropathy and paraproteinemic neuropathies. Curr Opin Neurol 1994;7:393-397.
79. Hartung H-P, Reiners K, Toyka KV, Pollard JD: Guillain-Barré syndrome and CIDP; in Hohlfeld R (ed): Immunology of Neuromuscular disease. Dordrecht, Kluwer, 1994, pp 39-104.
80. Vermeulen M, van der Meche FGA, Speelman JD, Weber A, Busch HFM: Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-326.
81. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD: High-dose intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-425.
82. van Doorn PA, Brand A, Strengers PRV, Meulstee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
83. Vedanarayanan W, Kandt RS, Darrell DV, DeLong GR: Chronic inflammatory demyelinating polyneuropathy of childhood: Treatment with high-dose intravenous immunoglobulin. Neurology 1991;41:828-830.
84. van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991; 48:217-220.
85. Vermeulen M, van Doom PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
86. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36: 838-845.
87. Choudhary PP, Hughes RAC: Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995;88:493-502.
88. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
89. Nobile-Orazio E: Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1996;60:599-603.
90. Kaji R, Oka N, Tsuji T, Mezaki T, Nishio T, Akiguchi I, Kimura J: Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993;33:152-158.
91. Krendel DA, Costigan DA: Multifocal motor neuropathy or CIDP? Ann Neurol 1993;34:750.
92. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN: A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
93. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S: Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994; 51:861-864.
94. Parry GJ, Clarke S: Multifocal acquired demyelinating neuropathy masquerading as motor neuron dissease. Muscle Nerve 1988;11:103-107.
95. Feldman EL, Bromberg MB, Albers JW, Pestronk A: Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
96. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J: Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-783.
97. Charles N, Benoit P, Vial C, Bierme T, Moreau T, Bady B: Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet 1992;340:182.
98. Kaji R, Shibasaki H, Kimura J: Mulitfocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy. Neurology 1992;42:506-509.
99. Chaudhry V, Corse AM, Comblath DR, Kund RW, Drachman DB, Freimer ML, Miller RG, Griffin JW: Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol 1993;33:237-242.
100. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G; High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-544.
101. Comi G, Amadio S, Galardi G, Fazio R, Nemni R: Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1994;57(suppl):35-37.
102. Léger JM, Ben Younes-Chennoufi A, Chassande B, Davila G, Bouche P, Baumann N, Brunet P: Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994;57(supp1):46-49.
103. Bouche P, Moulonguet A, Ben Younes-Chennoufi A, Adams D, Baumann N, Meininger V, Léger JM, Said G: Multifocal motor neuropathy with conduction block: A study of 24 patients J Neurol Neurosurg Psychiatry 1995;59:38-44.
104. Azulay J-P, Blin O, Pouget J, Boucraut J, Billé-Turc F, Carles G, Serratrice G: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 1994;44:429-432.
105. van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FGI, Wokke JHJ: Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
106. Elliott JL, Pestronk A: Progression of multifocal motor neuropathy during apparent successful treatment with human immunoglobulin. Neurology 1994;44:967-968.
107. van den Berg LH, Franssen H, Wokke JHJ: Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin. Neurology 1995;45:987-988.
108. Drachman DB: Myasthenia gravis. N Engl J Med 1994;330:1797-1810.
109. Fateh-Moghadam A, Besinger U, Geursen RG: Ein klinisches Modell zur Regulation der humoralen Immunantwort: Infusionstherapie. Beitr Infusionsther Klin Ernähr 1982;9:69-79.
110. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;ii:809.
111. Devathasan G, Kueh YK, Chong PN: High-dose intravenous gammaglobulin for myasthenia gravis Lancet 1984;ii:809-810.
112. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG: High-dose intravenous gammaglobulin for myasthenia gravis Lancet 1984;i:848-845.
113. Gajdos P, Outin H, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, Goulon M, Goulon-Goeau C, Morel E: High-dose intravenous gammaglobulin for myasthenia gravis Lancet 1984;i:406-407.
114. Arsura EL, Bick A, Brunner NG, Namba T, Grob D: High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
115. Besinger UA, Fateh-Moghadam A, Knorr-Held S, Wick M, Kissel H, Albiez M: Immunomodulation in myasthenia gravis by high-dose intravenous 7-S immunoglobulins Ann N Y Acad Sci 1987;505: 828-831.
116. Gajdos P, Outin HD, Morel E, Raphael JC, Goulon M: High-dose intravenous gamma globulin for myasthenia gravis: An alternative to plasma exchange? Ann N Y Acad Sci 1987;505:842-844.
117. Arsura EL, Bick A, Brunner NG, Grob D: Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
118. Cosi V, Lombardi M, Piccolo G, Erbetta A: Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84:81-84.
119. Fleischer E, Schumm F: Behandlung der generalisierten Myasthenie mit hochdosiertem Immunglobulin. Aktuel Neurol 1994;21:127-130.
120. Bamberg C, Janzen RWC, Szabados M: Zur Langzeitbehandlung mit 7S-Immunglobulinen bei Myasthenia gravis. Nervenarzt 1996;67:327-332.
121. Uchiyama M, Ichikawa Y, Takaya M, Moriuchi J, Shimizu H, Arimori S: High-dose gammaglobulin therapy of generalized myasthenia gravis. Ann N Y Acad Sci 1987;505:868-871.
122. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993;50:837-840.
123. Gajdos P: Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994;97(suppl 1):49-51.
124. Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, Barohn RJ: Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-586.
125. Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325: 1487-1498.
126. Askanas V, Engel WK, Mirabella M: Idiopathic inflammatory myopathies: Inclusion-body myositis, polymyositis, and dermatomyositis. Curr Opin Neurol 1994;7:448-456.
127. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ: Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-747.
128. Cherin P, Herson S, Wechsler B, Piette J-C, Bletry O, Coutellier A, Ziza J-M: Efficacy of intravenous gammaglobulin therapy in chronic refratory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991;91:162-168.
129. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM: Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991;91: 169-172.
130. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G: High-dose intravenous human immunoglobulins in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992;55:60-62.
131. Stoll T, Michel BY, Neidhart M, Wassmer P, Neidl K, Fehr K, Wagenhäuser FJ: Polymyositis: Krankheitsverlauf und Therapie mit intravenös applizierten Immunglobulinen. Schweiz Med Wochenschr 1992;122:1458-1465.
132. Cherin P, Herson S: Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994;57 (suppl):50-54.
133. Sansome A, Dubowitz V: Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995;72:25-28.
134. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore S, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
135. Soueidan SA, Dalakas MC: Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:875-879.
136. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahnek Z, Kissel JT: Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology 1994;44:1516-1518.
137. Dalakas MC: Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996;104(suppl 1):55-60.
138. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K: Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997;48:712-716.